Pfizer Bests Investor Suit Over Alzheimer's Drug Trial

Law360, New York (February 10, 2012, 6:47 PM EST) -- A New Jersey federal judge on Friday tossed a class action accusing Pfizer Inc. and former senior executives of Pfizer unit Wyeth of misleading investors about the performance of Wyeth’s highly publicized Alzheimer’s drug bapineuzumab in its clinical trial.

Granting Pfizer’s bid to dismiss the suit, U.S. District Judge Susan D. Wigenton said Wyeth had sufficiently cautioned investors in a May 2007 press release that they could not conclude enough about the effectiveness of bapineuzumab, or B-Mab, even though they had said the drug was planned...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.